CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (UNAUDITED) - USD ($) $ in Millions		Total		Common Stock	Treasury Stock		Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Equity Attributable to Noncontrolling Interests	Share Repurchase Program	[2]	Share Repurchase Program Treasury Stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Treasury stock, shares	[1]	22,300,000
Common Stock, Shares, Issued		501,900,000
Total equity		$ 2,185		$ 5	$ (1,487)		$ 1,026	$ 3,270	$ (629)	$ 0
Treasury Stock, Shares	[1]	22,300,000
Beginning balance at Dec. 31, 2018		$ 2,185		5	(1,487)		1,026	3,270	(629)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income		683						683		0
Other comprehensive loss		(40)							(40)
Share-based compensation awards	[2]	$ 39			55		(8)	(8)
Treasury stock acquired, shares	[1]	(3,100,000)	[3]								(1,400,000)
Treasury stock acquired	[3]	$ (300)			(300)	[2]
Employee benefit plan contribution from Pfizer Inc.	[4]	1					1
Dividends declared		(157)						(157)
Ending balance at Jun. 30, 2019		2,411		5	(1,732)		1,019	3,788	(669)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Total equity		2,411		5	(1,487)		1,026	3,270	(669)	0
Net income		683						683		0
Other comprehensive (loss)/income, net of tax		$ (40)							(40)
Treasury Stock, Shares, Acquired	[1]	3,100,000	[3]								1,400,000
Share-based compensation awards	[2]	$ 39			55		(8)	(8)
Treasury Stock, Value, Acquired, Cost Method	[3]	300			$ 300	[2]
Dividends, Common Stock		$ 157						157
Treasury stock, shares					22,900,000
Common Stock, Shares, Issued		501,900,000
Total equity		$ 2,317		5	$ (1,593)		1,008	3,495	(598)	0
Treasury Stock, Shares					22,900,000
Beginning balance at Mar. 31, 2019		2,317		5	$ (1,593)		1,008	3,495	(598)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income		371						371
Other comprehensive loss		(71)							(71)
Share-based compensation awards		22			$ 11		11
Treasury stock acquired, shares					(1,400,000)								(200,000)
Treasury stock acquired		(150)			$ (150)
Dividends declared		(78)						(78)
Ending balance at Jun. 30, 2019		2,411		5	(1,732)		1,019	3,788	(669)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Total equity		2,411		5	$ (1,732)		1,019	3,788	(669)	0
Net income		371						371
Other comprehensive (loss)/income, net of tax		(71)							(71)
Treasury Stock, Shares, Acquired					1,400,000								200,000
Share-based compensation awards		22			$ 11		11
Treasury Stock, Value, Acquired, Cost Method		150			150
Dividends, Common Stock		$ 78						78
Treasury stock, shares	[1]	24,100,000
Common Stock, Shares, Issued		501,900,000
Total equity		$ 2,411		5	$ (1,732)		1,019	3,788	(669)	0
Treasury Stock, Shares	[1]	24,100,000
Treasury stock, shares		26,363,033			26,400,000	[1]
Common Stock, Shares, Issued		501,891,243
Total equity		$ 2,708		5	$ (2,042)		1,044	4,427	(726)	0
Treasury Stock, Shares		26,363,033			26,400,000	[1]
Beginning balance at Dec. 31, 2019		$ 2,708		5	$ (2,042)		1,044	4,427	(726)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income		799						800		(1)
Other comprehensive loss		(130)							(130)	0
Share-based compensation awards	[2]	43			$ 47		(15)	11
Treasury stock acquired, shares	[1]				(1,800,000)	[3]							(1,300,000)	[2]
Treasury stock acquired	[3]	(250)			$ (250)
Employee benefit plan contribution from Pfizer Inc.	[4]	1					1
Dividends declared		(190)						(190)
Ending balance at Jun. 30, 2020		2,987		5	(2,245)		1,030	5,048	(856)	5
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Total equity		2,708		5	$ (2,245)		1,044	4,427	(726)	5
Net income		799						800		(1)
Other comprehensive (loss)/income, net of tax		(130)							(130)	0
Treasury Stock, Shares, Acquired	[1]				1,800,000	[3]							1,300,000	[2]
Share-based compensation awards	[2]	43			$ 47		(15)	11
Treasury Stock, Value, Acquired, Cost Method	[3]	250			$ 250
Dividends, Common Stock		$ 190						190
Treasury stock, shares					27,000,000.0
Common Stock, Shares, Issued		501,900,000
Total equity		$ 2,753		5	$ (2,252)		1,017	4,764	(781)	0
Treasury Stock, Shares					27,000,000.0
Beginning balance at Mar. 31, 2020		2,753		5	$ (2,252)		1,017	4,764	(781)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income		376						377		(1)
Other comprehensive loss		(75)							(75)
Consolidation of noncontrolling interests		6								6
Share-based compensation awards		22					13	2
Treasury stock acquired, shares													(100,000)
Dividends declared		(95)						(95)
Ending balance at Jun. 30, 2020		2,987		5	(2,245)		1,030	5,048	(856)	5
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Total equity		2,753		5	$ (2,245)		1,030	5,048	(856)	5
Net income		376						377		(1)
Other comprehensive (loss)/income, net of tax		(75)							(75)
Treasury Stock, Shares, Acquired													100,000
Share-based compensation awards		22					13	2
Dividends, Common Stock		$ 95						95
Treasury stock, shares		26,891,765			26,900,000	[1]
Common Stock, Shares, Issued		501,891,243
Total equity		$ 2,987		$ 5	$ (2,245)		$ 1,030	$ 5,048	$ (856)	$ 5
Treasury Stock, Shares		26,891,765			26,900,000	[1]

[1] Shares may not add due to rounding.

[2] Includes the issuance of shares of Zoetis Inc. common stock and the reacquisition of shares of treasury stock associated with exercises of employee share-based awards. Also includes the reacquisition of shares of treasury stock associated with the vesting of employee share-based awards to satisfy tax withholding requirements. For additional information, see Note 12. Share-based Payments and Note 13. Stockholders' Equity.

[3] Reflects the acquisition of treasury shares in connection with the share repurchase program. For additional information see Note 13. Stockholders' Equity.

[4] Represents contributed capital from Pfizer Inc. associated with service credit continuation for certain Zoetis Inc. employees in Pfizer Inc.'s U.S. qualified defined benefit and U.S. retiree medical plans.